Benefits
Standardized glucoraphanin delivery
Truebroc® standardizes to 13% glucoraphanin from broccoli seed — addressing the major issue with generic broccoli supplements (variable glucoraphanin content). Reproducible delivery enables consistent clinical effects.
Cardiovascular biomarker improvements
Clinical trials specifically using Truebroc® document improvements in cardiovascular biomarkers including blood pressure, oxidative stress markers, and inflammatory markers. Trial-validated for this specific branded form.
Autism behavioral support trials
Foundational sulforaphane autism research used broccoli sprout extracts and derived sulforaphane preparations, with Brassica Protection Products (Truebroc's parent company) providing research material in some studies. Important note: subsequent autism trials have used different formulations including Avmacol® (Nutramax Laboratories), which combines broccoli seed and broccoli sprout blend with active myrosinase — not Truebroc® specifically. The autism evidence base supports the broader glucoraphanin/sulforaphane mechanism rather than Truebroc® as a specific product. For autism-specific applications, products with active myrosinase or pre-formed sulforaphane may be more relevant than Truebroc® alone.
NRF2 activation and detoxification enzyme upregulation
Truebroc® clinical trials document NRF2 pathway activation and upregulation of detoxification enzymes (NQO1, HO-1) in humans. The mechanism-level validation supports the broader applications and theoretical health span effects.
Trial-validated quality control
Brassica Protection Products' standardization specifically supports the clinical trial validation. Different from generic broccoli extracts with unknown standardization or trial validation. Brand premium reflects research investment.
Manufacturing consistency advantage
Truebroc® provides reproducible glucoraphanin content batch-to-batch through documented quality control. Critical for applications where consistent dosing affects clinical outcomes — particularly the autism and cardiovascular trials.
Mechanism of action
In-vivo sulforaphane generation
Truebroc® glucoraphanin reaches the intestine where gut bacteria with myrosinase activity (or supplemented myrosinase) convert it to bioactive sulforaphane. Mechanism provides stable supplementation that generates the unstable active compound in vivo.
NRF2 pathway activation
Sulforaphane generated from Truebroc® activates the NRF2 master antioxidant pathway, upregulating dozens of detoxification and antioxidant enzymes for 24+ hours. Mechanism distinguishing from typical antioxidant supplements.
Standardized bioavailability
Truebroc® standardization produces reproducible plasma glucoraphanin levels and downstream sulforaphane generation. Important for consistent clinical effects across trials and consumer products.
Clinical trials
Clinical trials specifically using Truebroc® document improvements in cardiovascular biomarkers including blood pressure, oxidative stress, and inflammatory markers. Trial-validated for this branded form.
Foundational autism research (Singh et al. 2014, PNAS) used a broccoli sprout extract derived from Brassica's source material. Subsequent autism trials including the 2018 follow-up and various pediatric studies have used Avmacol® (Nutramax) which combines broccoli seed and sprout with active myrosinase. The evidence supports the sulforaphane mechanism for autism rather than Truebroc® as a specific product.
Clinical pharmacodynamic studies document NRF2 activation and detoxification enzyme upregulation in humans receiving Truebroc®. Mechanism-level validation supports broader applications.